Cited 37 times in
Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.